Eritema necrolítico migratorio como manifestación de tumor neuroendocrino de páncreas. Valoración clínico-radiológica

Gonzalo Dulcich; Marcos Alejandro  Mestas Nuñez; Ernestina Maria Jose  Gentile

doi:10.31053/1853.0605.v79.n2.32543

Authors

Gonzalo Dulcich Hospital Italiano de Buenos Aires
Marcos Alejandro Mestas Nuñez Hospital Italiano de Buenos Aires
Ernestina Maria Jose Gentile Hospital Italiano de Buenos Aires

DOI:

https://doi.org/10.31053/1853.0605.v79.n2.32543

Keywords:

glucagonoma, necrolytic migratory erythema, neuroendocrine tumors

Abstract

Glucagonoma is a neuroendocrine tumour of very low incidence, estimated at 1 case per 20 million people per year. It typically manifests with a clinical syndrome that includes a characteristic dermatosis called necrolytic migratory erythema (NME). We present the case of a 60-year-old male with NME as the initial presentation of a pancreatic tumour and its imaging findings. We emphasize the importance of recognizing the clinical features of NME and the role of different imaging methods for early diagnosis and correct management of these pancreatic tumours.

Downloads

Download data is not yet available.

Author Biographies

Gonzalo Dulcich, Hospital Italiano de Buenos Aires

27 year old Argentinean physician graduated with honours from the National University of Rosario, Rosario, Santa Fe, Argentina (2012 - 2018).Residence in Medical Imaging at the Hospital Italiano de Buenos Aires (“Italian Hospital of Buenos Aires”) currently second year resident. Buenos Aires, Argentina
Marcos Alejandro Mestas Nuñez, Hospital Italiano de Buenos Aires

28 year old Argentinean physician graduated with honours from the University of Buenos Aires, Autonomous City of Buenos Aires, Argentina (2011-2017).Residence in Medical Imaging at the Hospital Italiano de Buenos Aires (“Italian Hospital of Buenos Aires”) currently third year resident. Buenos Aires, Argentina
Ernestina Maria Jose Gentile, Hospital Italiano de Buenos Aires

Argentinean physician specialising in Diagnostic Imaging. Adjunct Professor at the Faculty of Medicine of the University of Buenos Aires, Buenos Aires, Argentina. Associate Physician at the Hospital Italiano de Buenos Aires (“Italian Hospital of Buenos Aires”), Buenos Aires, Argentina.

References

1. Braverman IM. "Cutaneous manifestations of internal malignant tumors" by Becker, Kahn and Rothman, June 1942. Commentary: Migratory necrolytic erythema. Arch Dermatol. 1982 Oct;118(10):784-98. doi: 10.1001/archderm.118.10.784.

2. Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet. 1974 Jul 6;2(7871):1-5. doi: 10.1016/s0140-6736(74)91343-9.

3. John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022. doi: 10.1111/jdv.13752.

4. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug;39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd.

5. Lobo I, Carvalho A, Amaral C, Machado S, Carvalho R. Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol. 2010 Jan;49(1):24-9. doi: 10.1111/j.1365-4632.2009.04220.x.

6. Buetow PC, Parrino TV, Buck JL, Pantongrag-Brown L, Ros PR, Dachman AH, Cruess DF. Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. AJR Am J Roentgenol. 1995 Nov;165(5):1175-9. doi: 10.2214/ajr.165.5.7572498.

7. Compton NL, Chien AJ. A rare but revealing sign: necrolytic migratory erythema. Am J Med. 2013 May;126(5):387-9. doi: 10.1016/j.amjmed.2013.01.012.

8. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004 Nov;151(5):531-7. doi: 10.1530/eje.0.1510531.

9. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed. 2004 Sep 10;6(3):4.

10. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975.

11. Buetow PC, Miller DL, Parrino TV, Buck JL. Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization. Radiographics. 1997 Mar-Apr;17(2):453-72; quiz 472A-472B. doi: 10.1148/radiographics.17.2.9084084. Erratum in: Radiographics 1997 Jul-Aug;17(4):1010.

12. Horton KM, Hruban RH, Yeo C, Fishman EK. Multi-detector row CT of pancreatic islet cell tumors. Radiographics. 2006 Mar-Apr;26(2):453-64. doi: 10.1148/rg.262055056.

13. Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011 Nov;21(11):2408-16. doi: 10.1007/s00330-011-2199-y.

14. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008 Jun;112(11):2447-55. doi: 10.1002/cncr.23469.

15. Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics. 2010 Oct;30(6):1445-64. doi: 10.1148/rg.306105523.